The observation that AngII-induced hypertension is significantly blunted in the absence of SPAK activity supports the proposal that strategies preventing SPAK–NCC interactions could be a new therapeutic avenue for hypertension [31]. The gene discussed is STK39; the disease is hypertensive disorder.